Aptahem’s collaboration with the research team at Örebro University has identified a pharmacologic mechanism of action for Apta-1
Aptahem AB (publ) announce today that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University to map the details behind Apta-1’s effects with the support from the Knowledge Foundation’s Prospect Call now has generated results that clarify one of Apta-1’s important mechanisms.
A scientifically sound mechanism of action is more or less necessary to obtain a final approval from national authorities.
“We have identified a pharmacologic mechanism of action for Apta-1, down to a molecular level, which should be significant to previous results in in vivo disease models” says Dr Magnus Grenegård, Professor in physiology at Örebro University, and he continues: “To scientifically identify the mechanisms behind therapeutically promising drug candidates can be more than meticulous from a research perspective. The next step is to submit our research results to have them reviewed by a significant scientific journal.”
Dr Luiza Jedlina, CSO at Aptahem, comments: ”We are very excited over the recent results presented to us by the group in Örebro, and we have had several discussions to ensure that we fully understand what these findings mean. The group in Örebro have been very enthusiastic and professional and we are very impressed with what they have achieved during our collaboration. These results are extremely important to Aptahem for regulatory purposes and to be able to enter the clinical phase.”
More information will be made public as soon as the findings have been published in a scientific journal.
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
About Cardiovascular Research Centre (CVRC), Örebro University
Cardiovascular Research Centre (CVRC) is a research environment founded in 2014 at the Örebro University and consists of about 30 scientists at the university and Region Örebro. CVRC’s overall goal is to increase the knowledge about disease mechanisms, more efficient diagnoses, treatment and prevention of cardiovascular diseases. Link to the CVRC at Örebro University: https://www.oru.se/english/research/research-environments/mh/cardiovascular-research-centre-cvrc/
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.